A Study of Antiaggregatory Effect of Antiplatelet Agents by Platelet Aggregation Test

J Korean Neurol Assoc > Volume 7(1); 1989 > Article

Journal of the Korean Neurological Association 1989;7(1): 249-255.

항혈소판제제의 혈소판 응집억제 효과에 관한 연구

이원용, 노재규,조한익,이상복,명호진

서울대학교 신경과, 임상병리학.

A Study of Antiaggregatory Effect of Antiplatelet Agents by Platelet Aggregation Test

Won-Yong Lee,M.D., Jae-Kyu Roh,M.D., Han-Ik Cho,M.D., Sang-Bok Lee,M.D., Ho-Jin Myung,M.D.

Department of neurology & clinical Pathology , College of medicine, Seoul National University

Abstract

We performed platelet aggregation test in sixty three patients (54 ; cerebral infarction, 9 ; transient ischemic attack) who were randomly treated with aspirin 300mg/day or dipyridamole 150mg/day, singlely or in combination or ticlopidine 500mg/day to evaluate the inhibitory effect of commonly used antiplatelet agents on platelet aggregation. All patients had normal baseline platelet aggregation responses to 4 stimuli ; adenosine diphosphate, epinephrine, collagen and ristocetin. Our study showed no inhibitory response to platelet aggregation at least 7 days after antiplatelet administration in 41.1% (14/34) of aspirin group, 9.5% (2/21) of ticlopidine group, and 100% (8/8) of dipyridamole group. In all of the 9 patients with normal aggregation response to aspirin therapy, platelet aggregation test was converted to inhibitory response by ticlopidine. In contrast, in all of the 2 patients with normal aggregation response to ticlopidine therapy, platelet aggregation test was converted to inhibitory response by aspirin. This study confirms previous findings of platelet inhibition by ticlopidine and aspirin in patients with ischemic cerebrovascular disease. And these results suggest that dipyridamole do not inhibit platelet aggregation in vivo.